EPIC Study results

objective

The EPIC (Evaluation of Pimobendan In dogs with Cardiomegaly) Study1 analysed whether long-term administration of pimobendan to
dogs with stage B2 myxomatous mitral valve disease (MMVD) and echocardiographic and radiographic evidence of cardiac enlargement
will delay onset of clinical signs of congestive heart failure (CHF), cardiac-related death, or euthanasia (composite primary endpoint).

study design

36 centres

centres

360 dogs

dogs

Double-blinded Placebo-controlled

double-blinded placebo-controlled

11 countries

countries

Over 5 years

years

findings

15-month delay

in time to composite primary endpoint compared with dogs receiving placebo*

60%more time

in asymptomatic stage B2
of heart disease*

10% more life

without CHF signs that impact quality of life or
cardiac-related death

This site uses cookies to improve your browsing experience. By using this site, you agree to their use.

Cookie Information
welcome to EPICtrial.com
Disclaimer

Are you a resident of the United States of America?

INFORMATION DISCUSSED ON EPICTRIAL.COM RELATES TO AN INDICATION THAT IS NOT REGISTERED IN THE USA.

You will now be redirected to a USA-specific website.